Tri-specific antibodies

US11649286B2 · kind B2 · utility

Assignees

• SystImmune, Inc. · US
• BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. · CN

Inventors

• Yi Zhu · Chengdu, CN
• Ole Olsen · Everett, US
• Dong Xia · Redmond, US
• David Jellyman · Duvall, US
• Katrina Bykova · Seattle, US
• Anne-Marie K. Rousseau · Seattle, US
• Bill Brady · Watertown, US
• Blair R. Renshaw · Renton, US
• Brian R. Kovacevich · Snohomish, US
• Yu Liang · Tokyo, JP
• Zeren Gao · Redmond, US

Key dates

• Filing date: Jun 22, 2018
• Grant date: May 16, 2023
• Expiry date: Jun 16, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/73
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The application provides tri-specific antibody monomers having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a Fab domain, a Fc domain, and a second scFv domain at the C-terminal. In one embodiment, the first scFv domain, the Fab domain, and the second scFv domain each has a binding specificity against a different antigen.